Dr. Nicholas A. Butowski on Convection-Enhanced Delivery of Nanoliposomal Irinotecan in Brain Cancer
Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Nicholas A. Butowski, MD, director, Translational Research in Neuro-Oncology, University of California, San Francisco, discusses the eligibility of patients with glioblastoma to receive a convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Butowski encourages any medical professional who is treating a patient with either a grade 3 or 4 recurrent brain tumor to refer that patient to an institution to receive nanoliposomal irinotecan. He adds while the treatment may take 2 or 3 hours, depending on the patient, the treatment is targeted with an MRI so medical professionals can be as accurate as possible.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
